BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer
BioClin Therapeutics, Inc. (BioClin), a privately-held clinical stage biotechnology company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody to treat solid tumors, specifically metastatic bladder cancer, announced today the appointments of Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer. This build out of the executive team follows the closing of a $30 million Series B financing announced last year.
Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma.
Dr. Abella has been actively involved in cancer clinical trials research for nearly 30 years, most recently at Gilead Sciences, Inc. and Amgen, Inc.
“Graeme and Steve are tremendous additions to our team,” said Stephen Lau, Chief Executive Officer of BioClin. “Their experience in building and leading organizations, combined with their extensive work in developing and commercializing products that address important patient needs will be instrumental as we enter our next phase of growth.”
“I am thrilled to join BioClin at this important time during the company’s evolution,” said Graeme Currie, Ph.D, BioClin’s Chief Operating Officer. “Developing and implementing the clinical development strategy and planning for registrational studies for B-701 for metastatic bladder cancer is our top priority. I look forward to helping advance this important therapeutic.”
“I am excited to join this team of professionals who are scientifically driven to improve treatment options for patients,” said Steve Abella, M.D., Chief Medical Officer of BioClin. “I was impressed by the team’s expertise and energy, and I look forward to taking a leadership role in shaping BioClin’s clinical development strategy as we advance B-701 in the clinic.”
Graeme Currie was most recently Vice President of Clinical Science and Operations at Dynavax Technologies Corp. Prior to that, he spent six years at Regeneron Pharmaceuticals as the Vice President of Clinical Project Management and Operations and oversaw operations for 16 molecules and multiple therapeutic areas. During his tenure, Graeme was closely associated with the development programs for Eylea® for Wet AMD and DME, Praluent® for hypercholesterolemia and Dupixent® for Atopic Dermatitis. Prior to Regeneron, Graeme was Vice President of Clinical Operations at Sepracor Inc. and at PDL Biopharma. Graeme also spent 6 years as a Director at Gilead Sciences Inc., working in Hepatitis developing Hepsera™ for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN Biopharmaceuticals Inc. and Glaxo Wellcome. Graeme received a BSc from the University of Salford, and a Ph.D. in Oncology from Aston University.
Esteban (Steve) Abella has been actively involved in cancer clinical trials research for nearly 30 years including most recently at Gilead Sciences Inc. At Gilead, Steve was a Senior Director leading non-hodgkin’s lymphoma and leukemia efforts, as well as serving as a core member of the oncology senior leadership team. Prior to that, he served as the Executive Director at Amgen Inc., predominately responsible for the white cell franchise (Neulasta®/Neupogen®) global development efforts across clinical research and medical affairs. His clinical experiences prior to joining industry include 15 years in academic oncology, serving as Professor of Pediatric Oncology, and Medicine at the Barbara Ann Karmanos Cancer Institute, focused on stem cell transplantation and oncology clinical trials. Steve completed his fellowship and residency training at Wayne State University School of Medicine after graduating with a degree in medicine from the Universidad Central del Este. He attended the University of Pennsylvania for undergraduate studies.
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer using multiple therapeutic approaches (as B-701 monotherapy, and in combination therapies with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor).
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
BioClin Therapeutics, Inc.
Chief Executive Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30 | Pressemelding
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr